Global Kidney Cancer Drugs Industry

Sep 08, 2011, 06:49 ET from Reportlinker

NEW YORK, Sept. 8, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Kidney Cancer Drugs Industry

http://www.reportlinker.com/p0611069/Global-Kidney-Cancer-Drugs-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_

This report analyzes the worldwide markets for Kidney Cancer Drugs in US$ Million. This report on 'Kidney Cancer Drugs' provides market analytics specifically for the "Renal Cell Carcinoma" (RCC) market, owing to its predominance among the various types of kidney cancers. The market for Renal Cell Carcinoma (RCC) drugs is analyzed by the two major drug classes, which include: Multikinase Inhibitors, and Other RCC drug Classes (including Immunomodulators; mTOR inhibitors; and other emerging drug classes). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2008 through 2017. The report profiles 19 companies including many key and niche players such as AVEO Pharmaceuticals, AstraZeneca Plc, Bayer Schering Pharma AG, Bristol-Myers Squibb Co., Onyx Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck-Serono, Novartis AG, Pfizer, Inc., and WILEX AG. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Data Interpretation & Reporting Level 3

Quantitative Techniques & Analytics 3

Product Definitions and Scope of Study 3

Multikinase Inhibitors 4

Other RCC drug Classes (including Immunomodulators; mTOR

inhibitors; and other emerging drug classes.) 4

2. KIDNEY CANCER - FACTSHEET 5

3. MARKET OVERVIEW 6

Current Market Scenario and Outlook 6

Multikinase Inhibitors Dominate the Market 7

Presently Approved Drugs for the Treatment of Advanced Renal

Cell Carcinoma (RCC) 7

US and Europe Leads RCC Drugs Market Worldwide 7

Kidney Cancer Bodes Significant Potential for Targeted Therapies 7

Leading Kidney Cancer Drugs 8

Pfizer's Sutent Tops the RCC Drugs Market 8

Table 1: Leading Kidney Cancer Drugs Worldwide (2009): Sales

for Sutent, Nexavar, Afinitor, Avastin, and Proleukin 9

GSK's Votrient Threatens Sutent's Dominance 9

Nexavar Dominates Second Line Treatment for RCC 10

Table 2: Leading Drugs in the Second Line Treatment of RCC

(2009): Market Share Breakdown for Nexavar, Torisel,

Afinitor, Avastin, and Others (includes corresponding

Graph/Chart) 10

Torisel Leads Third Line Treatment for RCC 10

Table 3: Leading Drugs in the Third Line Treatment of RCC

(2017E): Market Share Breakdown for Afinitor, Axitinib,

Avastin, Torisel, and Others (includes corresponding

Graph/Chart) 10

4. KIDNEY CANCER: A GLIMPSE INTO THE DISEASE, CAUSES, SYMPTOMS,

AND DIAGNOSIS 11

Kidney Cancer: Disease Overview 11

Causes 11

Symptoms and Signs 11

Stages 11

Renal Cell Carcinoma (RCC): The Most Common Kidney Cancer 12

Types 12

Symptoms and Signs 12

Diagnosis 12

5. KIDNEY CANCER TREATMENT 13

Surgical Treatment 13

Targeted Therapies 14

Multi-kinase Inhibitors 14

mTOR Inhibitors 14

Oral Targeted Therapies 15

Injectable Targeted Therapy 15

Pros and Cons of Targeted Therapies 15

Monoclonal Antibodies 15

Immunomodulators 16

Aldesleukin (Proleukin®) 16

Interferon alpha-2 (Roferon-A®) 16

6. PROFILES OF MAJOR KIDNEY CANCER DRUGS 17

Sutent (Sunitinib) 17

Sutent Vs. Interferon-alpha and IFN-alpha therapies 17

Nexavar (Sorafenib) 17

Torisel (Temsirolimus) 18

Votrient (Pazopanib) 18

Avastin (Bevacizumab) 18

Afinitor (Everolimus) 18

7. PIPELINE ANALYSIS 19

Kidney Cancer Pipeline: As of 2010 19

Select Pipeline Drugs - A Review 19

Axitinib (Pfizer) 19

Tivozanib (AVEO Pharmaceuticals) 19

RENCAREX (WILEX) 20

TroVax (Oxford BioMedica) 20

8. CANCER STATISTICS 21

Cancer Incidence - Statistics on New Cases 21

Table 4: Global Cancer Incidence by Region: 2009 (includes

corresponding Graph/Chart) 21

Table 5: Global Cancer Incidence by Income Group: 2009

(includes corresponding Graph/Chart) 22

Table 6: Cancer Incidence in Upper Middle Income Countries by

Site: 2009 (includes corresponding Graph/Chart) 22

Table 7: Cancer Incidence in Lower Middle Income Countries by

Site: 2009 (includes corresponding Graph/Chart) 23

Table 8: Cancer Incidence in High Income Countries by Site:

2009 (includes corresponding Graph/Chart) 24

9. RECENT INDUSTRY ACTIVITY AND PRODUCT APPROVALS 25

WILEX Grants Exclusive US Commercialisation Rights for

RENCAREX to Prometheus 25

AVEO Collaborates with Astellas to Develop and Commercialize

Tivozanib 25

WILEX Announces End Results of REDECT Phase 3 Registration

Trial with Redectane® 25

NICE Rejects Novartis' Kidney Cancer Drug Everolimus 26

GlaxoSmithKline Gains Conditional EU Approval for Votrient

(pazopanib) 26

Prometheus and Novartis Enters into Commercialization Agreement 26

Cipla Launches Soranib Cancer Medicine 26

Roche Acquires Genentech 27

Novartis' Afinitor® Obtains EC Approval for Advanced RCC

Treatment 27

Novartis Obtains FDA Approval for Afinitor 27

Roche Receives FDA Approval for Avastin in Combination with

Interferon-Alpha for RCC Treatment 27

Pfizer's Sutent Obtains Recommendation as First Line Treatment

for mRCC 28

GlaxoSmithKline Receives FDA Approval for Votrient 28

Oxford BioMedica's TroVax Fails Kidney Cancer Clinical Trial 28

Genomic Health to Collaborate with Pfizer for New Genomic Test 28

Roche's Avastin Bags European Approval for Renal Cancer Treatment 28

Wyeth's TORISEL Receives FDA Approval 29

AstraZeneca's Novel Cancer Drug, AZD2171, Dubbed Recentin 29

10. FOCUS ON SELECT GLOBAL PLAYERS 30

AVEO Pharmaceuticals (US) 30

AstraZeneca Plc. (UK) 31

Bayer Schering Pharma AG (Germany) 31

Bristol-Myers Squibb Co. (US) 32

Onyx Pharmaceuticals, Inc. (US) 32

F. Hoffmann-La Roche Ltd. (Switzerland) 33

GlaxoSmithKline Plc. (UK) 33

Merck-Serono (Switzerland) 34

Novartis AG (Switzerland) 34

Pfizer, Inc. (US) 34

WILEX AG (Germany) 35

11. GLOBAL MARKET PERSPECTIVE 36

Table 9: World Recent Past, Current & Future Analysis for

Renal Cell Carcinoma (RCC) Drugs by Geographic Region - US,

Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets

Independently Analyzed by Annual Sales Figures in US$ Million

for Years 2008 through 2017 (includes corresponding

Graph/Chart) 36

Table 10: World 10-Year Perspective for Renal Cell Carcinoma

(RCC) Drugs by Geographic Region - Percentage Breakdown of

Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and

Rest of World Markets for Years 2008, 2011 & 2017 (includes

corresponding Graph/Chart) 37

Table 11: World Recent Past, Current & Future Analysis for

Multikinase Inhibitors by Geographic Region - US, Canada,

Japan, Europe, Asia-Pacific, and Rest of World Markets

Independently Analyzed by Annual Sales Figures in US$ Million

for Years 2008 through 2017 (includes corresponding

Graph/Chart) 38

Table 12: World 10-Year Perspective for Multikinase Inhibitors

by Geographic Region - Percentage Breakdown of Dollar Sales

for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World

Markets for Years 2008, 2011 & 2017 (includes corresponding

Graph/Chart) 39

Table 13: World Recent Past, Current & Future Analysis for

Other RCC Drugs by Geographic Region - US, Canada, Japan,

Europe, Asia-Pacific, and Rest of World Markets Independently

Analyzed by Annual Sales Figures in US$ Million for Years 2008

through 2017 (includes corresponding Graph/Chart) 40

Table 14: World 10-Year Perspective for Other RCC Drugs by

Geographic Region - Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific, and Rest of World

Markets for Years 2008, 2011 & 2017 (includes corresponding

Graph/Chart) 41

12. THE UNITED STATES 42

A.Market Analysis 42

Cancer Statistics in the US 42

Cancer Incidence Statistics 42

Table 15: New Cancer Cases in the US by Affected Site: 2009 42

Table 16: New Cancer Cases in Males in US by Leading Site:

2009 (includes corresponding Graph/Chart) 44

Table 17: New Cancer Cases in Females in US by Leading

Site: 2009 (includes corresponding Graph/Chart) 45

Cancer Mortality Statistics 45

Table 18: Cancer Related Deaths in the US by Affected Site:

2009 45

Table 19: Cancer Related Deaths in Males in US by Leading

Site: 2009 (includes corresponding Graph/Chart) 47

Table 20: Cancer Related Deaths in Females in US by Leading

Site: 2009 (includes corresponding Graph/Chart) 47

Kidney Cancer Incidence Rates and Mortality Statistics 48

Table 21: Kidney Cancer Incidence Rates by Race/Ethnicity

per 10,000 Men (includes corresponding Graph/Chart) 48

Table 22: Kidney Cancer Incidence Rates by Race/Ethnicity

Per 10,000 Women (includes corresponding Graph/Chart) 48

Table 23: Kidney Cancer Mortality Rates by Race/Ethnicity

per 10,000 Men (includes corresponding Graph/Chart) 49

Table 24: Kidney Cancer Mortality Rates by Race/Ethnicity

Per 10,000 Women (includes corresponding Graph/Chart) 49

NCI Funding for Kidney Cancer on the Rise 50

Table 25: NCI's Annual Funding on Kidney Cancer Research

for Years 2007, 2008 & 2009 (includes corresponding Graph/

Chart) 50

Table 26: Allocation of Funds by Scientific/ Research Area

(2009) (includes corresponding Graph/Chart) 50

Strategic Corporate Developments 51

Focus on Select Major Players 54

B.Market Analytics 56

Table 27: The US Recent Past, Current & Future Analysis for

Renal Cell Carcinoma Drugs by Drug Class - Multikinase

Inhibitors and Others Markets Independently Analyzed by

Annual Sales Figures in US$ Million for Years 2008 through

2017 (includes corresponding Graph/Chart) 56

Table 28: The US 10-Year Perspective for Renal Cell

Carcinoma Drugs by Drug Class - Percentage Breakdown of

Dollar Sales for Multikinase Inhibitors and Others Markets

for Years 2008, 2011 & 2017 56

13. CANADA 57

A.Market Analysis 57

Cancer Incidence and Mortality Statistics in Canada 57

Table 29: Estimated New Cancer Cases by Type/Site Among

Canadian Men (2010) (includes corresponding Graph/Chart) 57

Table 30: Estimated New Cancer Cases by Type/Site Among

Canadian Women (2010) (includes corresponding Graph/Chart) 58

Table 31: Estimated Cancer Deaths by Type/Site Among

Canadian Men (2010) (includes corresponding Graph/Chart) 58

Table 32: Estimated Cancer Deaths by Type/Site Among

Canadian Women (2010) (includes corresponding Graph/Chart) 58

B.Market Analytics 59

Table 33: Canadian Recent Past, Current & Future Analysis

for Renal Cell Carcinoma Drugs by Drug Class - Multikinase

Inhibitors and Others Markets Independently Analyzed by

Annual Sales Figures in US$ Million for Years 2008 through

2017 (includes corresponding Graph/Chart) 59

Table 34: Canadian 10-Year Perspective for Renal Cell

Carcinoma Drugs by Drug Class - Percentage Breakdown of

Dollar Sales for Multikinase Inhibitors and Others Markets

for Years 2008, 2011 & 2017 59

14. JAPAN 60

Market Analysis 60

Table 35: Japanese Recent Past, Current & Future Analysis

for Renal Cell Carcinoma Drugs by Drug Class - Multikinase

Inhibitors and Others Markets Independently Analyzed by

Annual Sales Figures in US$ Million for Years 2008 through

2017 (includes corresponding Graph/Chart) 60

Table 36: Japanese 10-Year Perspective for Renal Cell

Carcinoma Drugs by Drug Class - Percentage Breakdown of

Dollar Sales for Multikinase Inhibitors and Others Markets

for Years 2008, 2011 & 2017 60

15. EUROPE 61

A.Market Analysis 61

Cancer Statistics in Europe 61

Table 37: Cancer Incidence in Europe by Site (2009)

(includes corresponding Graph/Chart) 61

Strategic Corporate Developments 62

B.Market Analytics 63

Table 38: European Recent Past, Current & Future Analysis

for Renal Cell Carcinoma Drugs by Geographic Region -

France, Germany, Italy, UK and Rest of Europe Markets

Independently Analyzed by Annual Sales Figures in US$

Million for Years 2008 through 2017 (includes corresponding

Graph/Chart) 63

Table 39: European 10-Year Perspective for Renal Cell

Carcinoma Drugs by Geographic Region - Percentage Breakdown

of Dollar Sales for France, Germany, Italy, UK, and Rest of

Europe Markets for Years 2008, 2011 & 2017 (includes

corresponding Graph/Chart) 64

Table 40: European Recent Past, Current & Future Analysis

for Renal Cell Carcinoma Drugs by Drug Class - Multikinase

Inhibitors and Others Markets Independently Analyzed by

Annual Sales Figures in US$ Million for Years 2008 through

2017 (includes corresponding Graph/Chart) 65

Table 41: European 10-Year Perspective for Renal Cell

Carcinoma Drugs by Drug Class - Percentage Breakdown of

Dollar Sales for Multikinase Inhibitors and Others Markets

for Years 2008, 2011 & 2017 65

15a. FRANCE 66

Market Analysis 66

Table 42: French Recent Past, Current & Future Analysis for

Renal Cell Carcinoma Drugs by Drug Class - Multikinase

Inhibitors and Others Markets Independently Analyzed by

Annual Sales Figures in US$ Million for Years 2008 through

2017 (includes corresponding Graph/Chart) 66

Table 43: French 10-Year Perspective for Renal Cell

Carcinoma Drugs by Drug Class - Percentage Breakdown of

Dollar Sales for Multikinase Inhibitors and Others Markets

for Years 2008, 2011 & 2017 66

15b. GERMANY 67

A.Market Analysis 67

Strategic Corporate Development 67

Focus on Select Major Players 67

B.Market Analytics 69

Table 44: German Recent Past, Current & Future Analysis for

Renal Cell Carcinoma Drugs by Drug Class - Multikinase

Inhibitors and Others Markets Independently Analyzed by

Annual Sales Figures in US$ Million for Years 2008 through

2017 (includes corresponding Graph/Chart) 69

Table 45: German 10-Year Perspective for Renal Cell

Carcinoma Drugs by Drug Class - Percentage Breakdown of

Dollar Sales for Multikinase Inhibitors and Others Markets

for Years 2008, 2011 & 2017 69

15c. ITALY 70

Market Analysis 70

Table 46: Italian Recent Past, Current & Future Analysis for

Renal Cell Carcinoma Drugs by Drug Class - Multikinase

Inhibitors and Others Markets Independently Analyzed by

Annual Sales Figures in US$ Million for Years 2008 through

2017 (includes corresponding Graph/Chart) 70

Table 47: Italian 10-Year Perspective for Renal Cell

Carcinoma Drugs by Drug Class - Percentage Breakdown of

Dollar Sales for Multikinase Inhibitors and Others Markets

for Years 2008, 2011 & 2017 70

15d. THE UNITED KINGDOM 71

A.Market Analysis 71

Kidney Cancer Statistics 71

Strategic Corporate Developments 71

Focus on Select Major Players 72

B.Market Analytics 73

Table 48: The UK Recent Past, Current & Future Analysis for

Renal Cell Carcinoma Drugs by Drug Class - Multikinase

Inhibitors and Others Markets Independently Analyzed by

Annual Sales Figures in US$ Million for Years 2008 through

2017 (includes corresponding Graph/Chart) 73

Table 49: The UK 10-Year Perspective for Renal Cell

Carcinoma Drugs by Drug Class - Percentage Breakdown of

Dollar Sales for Multikinase Inhibitors and Others Markets

for Years 2008, 2011 & 2017 74

15e. REST OF EUROPE 75

A.Market Analysis 75

Focus on Select Major Players 75

B.Market Analytics 76

Table 50: Rest of European Recent Past, Current & Future

Analysis for Renal Cell Carcinoma (RCC) Drugs by Drug Class -

Multikinase Inhibitors and Others Markets Independently

Analyzed by Annual Sales Figures in US$ Million for Years

2008 through 2017 (includes corresponding Graph/Chart) 76

Table 51: Rest of European 10-Year Perspective for Renal

Cell Carcinoma Drugs by Drug Class - Percentage Breakdown of

Dollar Sales for Multikinase Inhibitors and Others Markets

for Years 2008, 2011 & 2017 77

16. ASIA-PACIFIC 78

A.Market Analysis 78

Cancer Statistics in Asia-Pacific 78

Table 52: Cancer Incidence in Asia-Oceania by Site: 2009

(includes corresponding Graph/Chart) 78

Product Launch 79

B.Market Analytics 79

Table 53: Asia-Pacific Recent Past, Current & Future

Analysis for Renal Cell Carcinoma (RCC) Drugs by Drug Class -

Multikinase Inhibitors and Others Markets Independently

Analyzed by Annual Sales Figures in US$ Million for Years

2008 through 2017 (includes corresponding Graph/Chart) 79

Table 54: Asia-Pacific 10-Year Perspective for Renal Cell

Carcinoma Drugs by Drug Class - Percentage Breakdown of

Dollar Sales for Multikinase Inhibitors and Others Markets

for Years 2008, 2011 & 2017 80

17. REST OF WORLD 81

Market Analysis 81

Table 55: Rest of World Recent Past, Current & Future

Analysis for Renal Cell Carcinoma Drugs by Drug Class -

Multikinase Inhibitors and Others Markets Independently

Analyzed by Annual Sales Figures in US$ Million for Years

2008 through 2017 (includes corresponding Graph/Chart) 81

Table 56: Rest of World 10-Year Perspective for Renal Cell

Carcinoma Drugs by Drug Class - Percentage Breakdown of

Dollar Sales for Multikinase Inhibitors and Others Markets

for Years 2008, 2011 & 2017 81

COMPETITIVE LANDSCAPE

Total Companies Profiled: 19 (including Divisions/Subsidiaries - 20)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 10

Canada 1

Europe 8

Germany 2

The United Kingdom 3

Rest of Europe 3

Asia-Pacific (Excluding Japan) 1

------------------------------------------

To order this report:

Drug and Medication Industry: Global Kidney Cancer Drugs Industry

Drug and Medication Business News

More  Market Research Report

Check our  Industry Analysis and Insights

Contact:
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com